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of severe organ dysfunction related to ischemia/reperfusion
injury, acute rejection, and infection.1
In clinical practice, acceptable graft storage times are limit-
ed to around 6 hours. A recent report reaffirmed the occur-
rence of diminishing graft function after periods of storage in
excess of 4 hours.2 The strategy used for preservation of lung
grafts is important and has been the subject of much experi-
mental research over the past 10 years. It has been shown that
inflated lungs are able to maintain aerobic metabolism during
the period of cold ischemia.3 In contrast, solid organs such as
the liver and pancreas undergo anaerobic metabolism during
storage. Despite this, those organs can be stored safely for up
to 24 hours with current techniques, reflecting perhaps a bet-
ter understanding of the behavior of those organs during
ischemia and also their inherently more robust anatomic char-
acteristics. 
Much experimental work has been directed toward improv-
ing the quality of lung preservation, in particular the evalua-
tion of low-potassium dextran solution (LPD), University of
Wisconsin solution, Euro-Collins solution (EC), and
Wallwork blood-based solutions, each one in conjunction
with a variety of pharmacologic adjuncts. Although strong
evidence exists supporting the use of alternatives to the com-
monly used EC, the slow adoption of such knowledge into
clinical practice is somewhat alarming, as highlighted in a
recent survey of current clinical practice.4
Initial results from experimental lung transplantation in the
development and modification of LPD at our institution indi-
Lung transplantation is an established therapeutic modality
for end-stage lung diseases. In the immediate post-transplan-
tation period, life-threatening graft dysfunction occurs in up
to 20% of patients, a percentage that has remained largely
unchanged for several years. As reported by the International
Society for Heart and Lung Transplantation (ISHLT) in 1999,
the 5-year survival after lung transplantation is approximately
50%. The most important factor adversely affecting long-term
survival after lung transplantation is bronchiolitis obliterans
syndrome, which is generally considered to be a complex end
result of a chronic rejection process. However, about 15% of
patients die within the first 3 months after lung transplantation
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such as patient sex and age, type of transplant, and reason for
transplant (Table I). 
Lung function as assessed by PaO2/FIO2 was significantly
better in the LPD group (370 ± 133 mm Hg) than in the EC
group (310 ± 134 mm Hg; P = .017), despite significantly
longer total graft ischemic times in the LPD group (348 ± 69
minutes vs 298 ± 92 minutes; P = .024). Clearly, a very
important and clinically relevant end point is the development
of severe life-threatening graft dysfunction. All patients were
therefore categorized according to their PaO2/FIO2 ratios. A
PaO2/FIO2 ratio of less than 150 clearly represents severe graft
dysfunction after lung transplantation. In the EC group, 10 of
48 patients (20.8%) had a PaO2/FIO2 ratio less than 150,
whereas in the LPD group only 5 of 46 patients (10.9%) had
a PaO2/FIO2 ratio below 150. Therefore, significantly more
patients in the EC group demonstrated what would be clear-
ly recognized as life-threatening graft dysfunction after trans-
plantation than in the LPD group (P = .044). There was a
trend toward an improved APACHE score in the LPD group
(LPD = 18.1 ± 5.3 vs EC = 24.6 ± 7.8; P = .08) and also a
trend toward a lower 30-day mortality (P = .082) in the LPD
group (LPD, n = 3/46, 6.5%; EC, n = 5/48, 10.4%). 
Comment. Graft preservation with LPD demonstrated
improved lung function in the early phase after clinical lung
transplantation compared with EC, despite significantly
longer ischemic times. This superior outcome with LPD is
consistent with evidence from experimental lung transplant
studies that LPD is superior to EC for lung preservation.5
Experimental data suggest longer safe ischemic times are
possible with LPD than EC. To our knowledge, this is the first
report that supports these findings in clinical lung transplan-
tation as well. The initial choice of EC as a lung preservation
solution was based on the experimental evidence available at
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cated that dextran 40 and low potassium concentration both
contribute significantly to uniformly excellent 12-hour lung
preservation and post-transplantation function seen with LPD
compared with EC.5 We have subsequently demonstrated that
standard LPD is less cytotoxic than EC, that LPD enables
higher levels of metabolic activity in recovering isolated alve-
olar type II epithelial cells, and that dextran does not act as a
superoxide radical scavenging mechanism.6 These and other
results by various other investigators in experimental lung
transplantation using LPD confirm the potential for improved
human lung preservation.
Encouraged by our own observations and those of other
groups, the Toronto Lung Transplant Program has now adopt-
ed LPD preservation solution into clinical practice after
approval was obtained for the use of LPD in clinical lung
transplantation in April 1998. This article reports our initial
experience with the use of LPD in comparison with EC in 94
lung clinical lung transplant procedures.
Methods and results. Data were prospectively recorded for
108 consecutive lung transplant procedures performed between
May 1996 and November 1999. All patients who received sin-
gle lung transplants were removed from this analysis (n = 13).
This was done to avoid the potential confounding influence on
overall oxygenation of the remaining native lung in patients
after single lung transplantation. Unequivocal evaluation of
transplanted lung function after ischemic preservation and
transplantation is possible only in patients who receive either
heart-lung or bilateral lung transplants. One patient with bron-
chiolitis obliterans, who received a re-transplant, was also
excluded from the study. The outcome of 46 procedures after
graft preservation with LPD (Perfadex, Vitrolife, Uppsala,
Sweden) was compared with the results after transplantation for
48 procedures performed with EC (Baxter Healthcare Corp,
Pharmacy Division, Deerfield, Ill) for graft preservation.
Alprostadil (prostaglandin E1, Prostin VR; Upjohn, Don Mills,
Ontario, Canada) was used before lung flush and in the flush
solution (0.5 mg each). Lungs were flushed with 4 L of preser-
vation solution and stored in preservation solution in an inflated
state. Since 1996, inhaled nitric oxide was used as indicated for
severe graft dysfunction. From December 1997 on, all patients
in our program were enrolled in an ongoing double-blind ran-
domized controlled trial on the use of inhaled nitric oxide after
transplantation; therefore, half received nitric oxide and half
received placebo. 
For the purpose of this study, the primary end point was ini-
tial post-transplantation graft function as assessed by arterial
oxygen tension/inspired oxygen fraction (PaO2/FIO2) ratio on
arrival in the intensive care unit. Secondary end points includ-
ed APACHE (Acute Physiology and Chronic Health
Evaluation) score on arrival in the intensive care unit and 30-
day survival. Age, sex, indication for transplant, type of trans-
plant (bilateral or heart-lung transplants), and total graft
ischemic times were also compared between these two
groups. The results were analyzed by analysis of variance
(continuous data) or the Fisher exact test (categoric data) and
are expressed as the mean ± standard deviation.
Although this was not a randomized trial, the two groups
were reasonably evenly matched for important risk factors,
Table I.  Demographic patient data in group 
comparison
LPD group EC group
Age (y)
Mean 44 44
Range 12-68 15-67
Sex (n)
Female patients 30 21
Male patients 24 33
Type of transplant (n)
Single lung transplant 7 6
Bilateral lung transplant 45 47
Heart-lung transplant 2 1
Reason for transplant (n)
Emphysema 20 15
Cystic fibrosis 13 16
Idiopathic pulmonary fibrosis 10 8
Primary pulmonary fibrosis 5 6
Sarcoidosis 1 1
Bronchiectasis 3 2
Lymphangioleiomyomatosis 1 1
Idiopathic bronchiolitis obliterans 1 5
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the conception of clinical transplantation in the early 1980s.
Although we acknowledge that a randomized study might
provide more compelling data, we did not believe that such a
study could be ethically justified given the wealth of data now
available demonstrating the clear benefit of LPD in experi-
mental studies. All data in this study were collected prospec-
tively in a mature lung transplant program without a learning
curve on equally matched study groups; these features indi-
cate the strengths of our study. Our surgical judgment is that
LPD provides better lung preservation than EC in clinical
lung transplantation, and we are very satisfied with the switch
to LPD in clinical practice. In future studies we hope to pro-
vide long-term follow-up results on the use of LPD in clini-
cal lung transplantation. These data will ideally determine
whether this improved early graft function is translated into
decreased long-term graft dysfunction in transplanted lungs. 
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